Forte Biosciences (FBRX) Price & Analysis

Compare

323 Followers

FBRX Stock Chart & Stats

$20.25

-$0.92(-4.43%)

At close: Jan 08 4:00 PM EST

$20.25

-$0.92(-4.43%)

Day’s Range― - ―

52-Week Range$4.90 - $25.97

Previous CloseN/A

Volume20.10K

Average Volume (3M)97.46K

Market Cap

$135.64M

Enterprise Value$45.71M

Total Cash (Recent Filing)$93.41M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.64

Next Earnings

Mar 24, 2026

EPS Estimate

-1.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.99

Shares Outstanding12,432,854

10 Day Avg. Volume83,173

30 Day Avg. Volume97,456

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)1.26

Price to Sales (P/S)0.00

P/FCF Ratio-2.15

Enterprise Value/Market Cap0.34

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-831.05

Enterprise Value/Ebitda-0.87

Forecast

1Y Price Target

$65.00

Price Target Upside220.99% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Biotech Sector RecoveryThe biotech sector is recovering, leading to a notable re-rating in development-stage microcap companies.

Product Development FocusForte Biosciences Inc. is fully focused on developing their CD122 antibody, FB102, which is a key component in IL-15 and IL-2 signaling.

Strategic PositioningForte Biosciences Inc. is positioned attractively within the recovering biotech sector, particularly with important proof of concept data expected.

Bears Say

Past Trials ConcernsThere are investor concerns regarding the past failures of IL-15/CD122 trials, impacting the stock's performance.

R&D Expenses ImpactQ3 operating expenses were above estimates due to increased research and development expenses.

Forte Biosciences News

Forte Biosciences initiated with an Outperform at Evercore ISI

Evercore ISI initiated coverage of Forte Biosciences (FBRX) with an Outperform rating and $65 price target There has...

17d ago

FBRX

Forte Biosciences reports Q3 EPS (99c), consensus ($1.07)

“We continue to make excellent progress with FB102,” said Forte Biosciences (FBRX) CEO Paul Wagner. “The US IND...

28d ago

FBRX

Forte Biosciences Reports Increased R&D Costs Amid Clinical Progress

Forte Biosciences Inc. ( ($FBRX) ) has released its Q3 earnings. Here is a breakdown of the information...

27d ago

FBRX

Forte Biosciences Inc. Launches Promising Study on Alopecia Areata Treatment

Forte Biosciences Inc. (($FBRX)) announced an update on their ongoing clinical study. Forte Biosciences Inc. is conducting a...

2M ago

FBRX

Forte Biosciences Advances Celiac Disease Treatment with FB102 Study

Forte Biosciences Inc. (($FBRX)) announced an update on their ongoing clinical study. Forte Biosciences Inc. is currently conducting...

2M ago

FBRX

Forte Biosciences’ FB102 Study: A Potential Breakthrough in Vitiligo Treatment

Forte Biosciences Inc. (($FBRX)) announced an update on their ongoing clinical study. Forte Biosciences Inc. is conducting a...

2M ago

FBRX

Forte Biosciences Reports Q2 2025 Financial Results

Forte Biosciences Inc. ( ($FBRX) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

FBRX

Forte Biosciences initiated with a Buy at Guggenheim on FB102 potential

As previously reported, Guggenheim initiated coverage of Forte Biosciences (FBRX) with a Buy rating and $75 price target...

4M ago

FBRX

Forte Biosciences initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Forte Biosciences (FBRX) with a Buy rating and $75 price target Published first on...

4M ago

FBRX

Forte Biosciences Announces Q2 2025 Results and Trials

The latest update is out from Forte Biosciences ( ($FBRX) ). On August 14, 2025, Forte Biosciences announced...

4M ago

FBRX

Forte Biosciences reports Q2 EPS (96c), consensus ($1.11)

“I am deeply appreciative of the Forte team’s incredible accomplishments in initiating 3 clinical trials for FB102 with...

4M ago

FBRX

Sixteen new option listings on July 23rd

New option listings for July 23rd include ABVC Biopharma Inc (ABVC), Astex Pharmaceuticals Inc (ASTX), Bitmine Immersion Technologies...

5M ago

RAL

SMU

Forte Biosciences Announces Public Offering of Shares

Forte Biosciences ( ($FBRX) ) just unveiled an update. On June 24, 2025, Forte Biosciences announced a public...

6M ago

FBRX

Forte Biosciences announces common stock offering, no amount given

Forte Biosciences (FBRX) announced that it has commenced an underwritten public offering of shares of its common stock...

6M ago

FBRX

FBRX FAQ

What was Forte Biosciences Inc.’s price range in the past 12 months?

Forte Biosciences Inc. lowest stock price was $4.90 and its highest was $25.97 in the past 12 months.

What is Forte Biosciences Inc.’s market cap?

Forte Biosciences Inc.’s market cap is $135.64M.

When is Forte Biosciences Inc.’s upcoming earnings report date?

Forte Biosciences Inc.’s upcoming earnings report date is Mar 24, 2026 which is in 102 days.

How were Forte Biosciences Inc.’s earnings last quarter?

Forte Biosciences Inc. released its earnings results on Nov 14, 2025. The company reported -$0.99 earnings per share for the quarter, beating the consensus estimate of -$1.068 by $0.078.

Is Forte Biosciences Inc. overvalued?

According to Wall Street analysts Forte Biosciences Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Forte Biosciences Inc. pay dividends?

Forte Biosciences Inc. does not currently pay dividends.

What is Forte Biosciences Inc.’s EPS estimate?

Forte Biosciences Inc.’s EPS estimate is -1.18.

How many shares outstanding does Forte Biosciences Inc. have?

Forte Biosciences Inc. has 12,432,854 shares outstanding.

What happened to Forte Biosciences Inc.’s price movement after its last earnings report?

Forte Biosciences Inc. reported an EPS of -$0.99 in its last earnings report, beating expectations of -$1.068. Following the earnings report the stock price went up 1.734%.

Which hedge fund is a major shareholder of Forte Biosciences Inc.?

Currently, no hedge funds are holding shares in FBRX

Forte Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-110.72%

Trailing 12-Months

Asset Growth

313.31%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Forte Biosciences Inc.

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Forte Biosciences (FBRX) Earnings & Revenues

Historic Earnings Reports

FBRX Stock 12 Month Forecast

Average Price Target

$65.00

▲(220.99% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","66":"$66","18.75":"$18.75","34.5":"$34.5","50.25":"$50.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,18.75,34.5,50.25,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.94,16.944615384615386,20.94923076923077,24.953846153846158,28.958461538461542,32.963076923076926,36.96769230769231,40.972307692307695,44.97692307692308,48.98153846153846,52.98615384615385,56.99076923076923,60.99538461538462,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.94,16.944615384615386,20.94923076923077,24.953846153846158,28.958461538461542,32.963076923076926,36.96769230769231,40.972307692307695,44.97692307692308,48.98153846153846,52.98615384615385,56.99076923076923,60.99538461538462,{"y":65,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.94,16.944615384615386,20.94923076923077,24.953846153846158,28.958461538461542,32.963076923076926,36.96769230769231,40.972307692307695,44.97692307692308,48.98153846153846,52.98615384615385,56.99076923076923,60.99538461538462,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.69,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.78,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.84,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.72,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.71,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.89,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.83,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >